Buch, Englisch, 506 Seiten, Format (B × H): 155 mm x 235 mm, Gewicht: 1063 g
Molecular Targets and Clinical Applications, Second Edition
Buch, Englisch, 506 Seiten, Format (B × H): 155 mm x 235 mm, Gewicht: 1063 g
ISBN: 978-1-58829-737-2
Verlag: Humana Press
In the second edition of their critically acclaimed book, Ronald Bukowski, Robert Motzer, and Robert Figlin have thoroughly updated and expanded their survey of clinical, biological and pathological management of localized and advanced renal cell carcinoma. A panel of internationally renowned contributors explores the latest developments in molecular genetics, focusing on the novel targets that have been discovered in epithelial renal tumors. The discussion includes the specific biology of selected target molecules or receptors and the various agents that inhibit these targets, including full chapters devoted to drugs that selectively inhibit receptor tyrosine kinases, such as sunitinib and axitinib. Further attention is paid to leading-edge strategies that target and inhibit tumor associated angiogenesis and block the vascular endothelial growth factor pathway. Comprehensive and authoritative, Renal Cell Carcinoma: Molecular Targets and Clinical Applications, Second Edition is the definitive text on the rapidly evolving landscape of experimental therapeutics, written and edited by the pioneers of the field.
Zielgruppe
Professional/practitioner
Autoren/Hrsg.
Fachgebiete
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Bildgebende Verfahren, Nuklearmedizin, Strahlentherapie Nuklearmedizin, PET, Radiotherapie
Weitere Infos & Material
Ch 1. Targeted Therapy for Metastatic Renal Cell Carcinoma: Overview
Ronald M. Bukowski, Robert A. Figlin, and Robert Motzer
Ch 2. Molecular Genetics of Inherited Renal Cell Carcinoma: Identification of Targets in the Hereditary Syndromes
W. Marston Linehan, Nadeem Dhanani, Cathy Vocke, and Gennady Bratslavsky
Ch 3. Molecular Targets in Renal Tumors: Pathologic Assessment
Ming Zhou
4.Cytokines: Therapeutic Results and Molecular Basis of Activity
Thomas Hutson and Ernest C. Borden
Ch 5. VHL and HIF in Clear Cell Carcinoma: Molecular Abnormalities and Potential Clinical Applications
William Kaelin and Daniel J. George
Ch 6. Vascular Endothelial Growth Factor (VEGF): Biologic Aspects and Clinical Approaches
W. Kimryn Rathmell and Brian Rini
Ch 7A. VEGF and PDGF Receptors: Biologic Relevance and Clinical Approaches to Inhibition
John S. Lam, Robert Figlin, and Arie Belldegrun
Ch 7B. Sunitinib and Axitinib in Renal Cell Carcinoma
Robert Motzer
Ch 7C. Sorafenib in Renal Cell Carcinoma
Saby George and Ronald M. Bukowski
Ch 7D. Additional Tyrosine Kinase Inhibitors in Renal Cell Carcinoma:
Brian Rini
Ch 8. Integrin a5ß1 as a Novel Therapeutic Target in Renal Cell Carcinoma
Vanitha Ramakrishnan, Vinay Bhaskar, Melvin Fox, Keith Wilson, John Cheville, and Barbara Finck
Ch 9A. Carbonic Anydrase IX: Biological and Clinical Approaches
Arie Belldegrun, Robert A. Figlin, and Brian Shuch
Ch 9B. Monoclonal Antibody G250 Recognizing Carbonic Anhydrase IX in Renal Cell Carcinoma: Biologic and Clinical Studies
Jeannette C. Oosterwijk-Wakka, Otto C. Boerman, Peter F. A. Mulders, and Egbert Oosterwijk
Ch 10. Chemokines in Renal Cell Carcinoma: Implications for Tumor Angiogenesis and Metastasis
Karen Reckamp, Robert A. Figlin, and Robert M. Strieter
Ch 11. PI3K/Akt/mTOR Pathway: A Growth Proliferation Pathway
Daniel Cho, James Mier, and Michael B. Atkins
Ch 12. EGFR/HER2: Relevance in Renal Cell Carcinoma
Eric Jonasch and Cheryl Walker
Ch 13. Proteosome - NFkB Signaling Pathway: Relevance in Renal Cell Carcinoma
Ram Ganapathi, Susan A.J. Vaziri, and Jorge Garcia
Ch 14. The Role of Hepatocyte Growth Factor Pathway Signaling in Renal Cell Carcinoma
Donald P. Bottaro, Benedetta Peruzzi, and Jean-Baptise Lattouf
Ch 15. Smac/DIABLO: A Proapoptotic Molecular Target in Renal Cell Carcinoma
Yoichi Mizutani, Akihiro Kawauchi, Benjamin Bonavida, and Tsuneharu Mmiki
Ch 16. EpH2A: A Novel Target in Renal Cell Carcinoma
Mayumi Kawabe, Christopher Herrem, James Finke, and Walter Storkus
Ch 17. Restoring Host Immunity: How Coregulatory Molecules are Changing the Approach to Management of Renal Cell Carcinoma
Brant A. Inman, Xavier Frigola, Haidong Dong, James C.Yang, and Eugene Kwon
Ch 18. The Role of Gangliosides in Renal Cell Carcinoma
Phillip Shaheen, Ronald M. Bukowski, and James Finke
Ch 19. Tumor Necrosis Factor – Misnomer and Therapeutic Target
Marina Parton, Tanya Das, Gaurisankar Sa, James Finke, Tim Eisen, and Charles Tannenbaum
Ch 20. Molecularly Targeted Staging Strategies in Renal Cell Carcinoma
Mark Nogueira and Hyung Kim
21. Adjuvant therapy for Renal Cell Carcinoma: Targeted Approaches
Karin Kader and Christopher Wood
